Loading...

IBEX Technologies

DB:IBT
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IBT
DB
CA$4M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • IBEX Technologies has significant price volatility in the past 3 months.
IBT Share Price and Events
7 Day Returns
-1.1%
DB:IBT
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-37.2%
DB:IBT
-9.2%
DE Biotechs
-6.7%
DE Market
IBT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
IBEX Technologies (IBT) -1.1% -18.4% 1.1% -37.2% 9.4% 181.8%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • IBT underperformed the Biotechs industry which returned -9.2% over the past year.
  • IBT underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
IBT
Industry
5yr Volatility vs Market

IBT Value

 Is IBEX Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of IBEX Technologies to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for IBEX Technologies.

DB:IBT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 9.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:IBT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 26.5%) (27.44%))
1.502
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.5
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.502 * 5.96%)
9.18%

Discounted Cash Flow Calculation for DB:IBT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for IBEX Technologies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:IBT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CAD, Millions) Source Present Value
Discounted (@ 9.18%)
2019 0.51 Est @ 49.41% 0.47
2020 0.68 Est @ 34.66% 0.57
2021 0.85 Est @ 24.33% 0.65
2022 1.00 Est @ 17.1% 0.70
2023 1.12 Est @ 12.04% 0.72
2024 1.21 Est @ 8.49% 0.71
2025 1.28 Est @ 6.01% 0.69
2026 1.34 Est @ 4.28% 0.66
2027 1.38 Est @ 3.06% 0.63
2028 1.41 Est @ 2.21% 0.59
Present value of next 10 years cash flows CA$6.39
DB:IBT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= CA$1.41 × (1 + 0.23%) ÷ (9.18% – 0.23%)
CA$15.77
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CA$15.77 ÷ (1 + 9.18%)10
CA$6.55
DB:IBT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CA$6.39 + CA$6.55
CA$12.94
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$12.94 / 24.77
CA$0.52
DB:IBT Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:IBT represents 0.62x of TSXV:IBT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.62x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (CAD) x Listing Adjustment Factor
= CA$ 0.52 x 0.62
€0.32
Value per share (EUR) From above. €0.32
Current discount Discount to share price of €0.09
= -1 x (€0.09 - €0.32) / €0.32
71.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price IBEX Technologies is available for.
Intrinsic value
>50%
Share price is €0.093 vs Future cash flow value of €0.32396
Current Discount Checks
For IBEX Technologies to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • IBEX Technologies's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • IBEX Technologies's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for IBEX Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are IBEX Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:IBT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in CAD CA$0.00
TSXV:IBT Share Price ** TSXV (2019-04-18) in CAD CA$0.15
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of IBEX Technologies.

DB:IBT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:IBT Share Price ÷ EPS (both in CAD)

= 0.15 ÷ 0.00

151.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IBEX Technologies is overvalued based on earnings compared to the Europe Biotechs industry average.
  • IBEX Technologies is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does IBEX Technologies's expected growth come at a high price?
Raw Data
DB:IBT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 151.06x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
34.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for IBEX Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on IBEX Technologies's assets?
Raw Data
DB:IBT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in CAD CA$0.31
TSXV:IBT Share Price * TSXV (2019-04-18) in CAD CA$0.15
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:IBT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:IBT Share Price ÷ Book Value per Share (both in CAD)

= 0.15 ÷ 0.31

0.49x

* Primary Listing of IBEX Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IBEX Technologies is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess IBEX Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. IBEX Technologies has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IBT Future Performance

 How is IBEX Technologies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover IBEX Technologies, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is IBEX Technologies expected to grow at an attractive rate?
  • IBEX Technologies's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • IBEX Technologies's earnings growth is expected to exceed the Germany market average.
  • Unable to compare IBEX Technologies's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:IBT Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:IBT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 34.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:IBT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:IBT Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-01-31 5 1 0
2018-10-31 5 0 0
2018-07-31 5 0 0
2018-04-30 5 0 2
2018-01-31 5 0 2
2017-10-31 5 1 3
2017-07-31 5 1 3
2017-04-30 5 1 1
2017-01-31 4 0 0
2016-10-31 4 1 0
2016-07-31 4 1 0
2016-04-30 5 2 1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • IBEX Technologies's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if IBEX Technologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:IBT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from IBEX Technologies Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IBT Past Financials Data
Date (Data in CAD Millions) EPS *
2019-01-31 0.00
2018-10-31 -0.02
2018-07-31 0.00
2018-04-30 0.15
2018-01-31 0.11
2017-10-31 0.13
2017-07-31 0.12
2017-04-30 0.02
2017-01-31 0.01
2016-10-31 0.00
2016-07-31 0.00
2016-04-30 0.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if IBEX Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess IBEX Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
IBEX Technologies has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IBT Past Performance

  How has IBEX Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare IBEX Technologies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • IBEX Technologies has delivered over 20% year on year earnings growth in the past 5 years.
  • IBEX Technologies's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • IBEX Technologies's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.
Earnings and Revenue History
IBEX Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from IBEX Technologies Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IBT Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 5.13 0.02 1.77 0.32
2018-10-31 4.59 -0.43 1.83 0.26
2018-07-31 4.73 -0.10 1.73 0.25
2018-04-30 4.92 2.28 1.95 0.19
2018-01-31 4.65 2.07 2.04 0.20
2017-10-31 5.30 2.91 1.88 0.19
2017-07-31 5.33 2.98 1.91 0.20
2017-04-30 4.73 0.63 1.70 0.21
2017-01-31 4.31 0.16 1.66 0.24
2016-10-31 3.91 -0.06 1.72 0.25
2016-07-31 4.11 0.10 1.71 0.27
2016-04-30 4.50 1.03 1.53 0.33
2016-01-31 4.70 1.20 1.58 0.37
2015-10-31 4.28 0.82 1.64 0.41
2015-07-31 3.49 0.21 1.72 0.44
2015-04-30 3.24 -0.94 1.89 0.39
2015-01-31 3.49 -0.51 1.82 0.37
2014-10-31 3.69 -0.33 1.89 0.37
2014-07-31 3.94 -0.48 1.93 0.38
2014-04-30 4.15 0.30 1.87 0.41
2014-01-31 4.27 0.03 2.14 0.45
2013-10-31 4.09 -0.43 2.19 0.43
2013-07-31 3.97 0.04 2.02 0.37
2013-04-30 3.55 -0.60 1.94 0.34
2013-01-31 3.08 -0.26 1.53 0.24
2012-10-31 2.93 0.15 1.27 0.23
2012-07-31 2.92 0.23 1.22 0.25
2012-04-30 2.90 0.61 1.12 0.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • IBEX Technologies has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • IBEX Technologies used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • It is difficult to establish if IBEX Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess IBEX Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
IBEX Technologies has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IBT Health

 How is IBEX Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up IBEX Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • IBEX Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • IBEX Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of IBEX Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from IBEX Technologies Company Filings, last reported 2 months ago.

DB:IBT Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 7.65 1.02 3.33
2018-10-31 7.60 1.03 2.86
2018-07-31 7.79 1.04 3.14
2018-04-30 7.79 1.03 2.70
2018-01-31 7.54 1.00 2.71
2017-10-31 7.91 1.06 3.11
2017-07-31 7.75 1.04 3.00
2017-04-30 5.46 1.15 3.00
2017-01-31 5.40 1.11 3.11
2016-10-31 5.01 1.16 2.88
2016-07-31 4.78 1.14 2.90
2016-04-30 4.72 1.10 2.92
2016-01-31 5.35 1.25 3.07
2015-10-31 5.03 1.17 2.64
2015-07-31 4.67 1.19 2.08
2015-04-30 3.59 1.10 1.17
2015-01-31 3.94 1.17 1.43
2014-10-31 3.96 1.05 1.75
2014-07-31 4.17 1.03 1.69
2014-04-30 4.38 1.04 1.44
2014-01-31 4.25 1.07 1.39
2013-10-31 4.16 1.01 1.73
2013-07-31 4.54 1.00 1.58
2013-04-30 3.95 0.99 1.37
2013-01-31 4.03 0.99 1.72
2012-10-31 4.49 0.00 2.15
2012-07-31 4.42 0.00 1.98
2012-04-30 4.50 0.00 2.12
  • IBEX Technologies's level of debt (13.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (25.1% vs 13.3% today).
  • Debt is well covered by operating cash flow (68%, greater than 20% of total debt).
  • Unable to confirm if the interest payments on IBEX Technologies's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess IBEX Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. IBEX Technologies has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IBT Dividends

 What is IBEX Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from IBEX Technologies dividends.
If you bought €2,000 of IBEX Technologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate IBEX Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate IBEX Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:IBT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as IBEX Technologies has not reported any payouts.
  • Unable to verify if IBEX Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of IBEX Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as IBEX Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess IBEX Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can IBEX Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. IBEX Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IBT Management

 What is the CEO of IBEX Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Baehr
COMPENSATION CA$231,411
AGE 75
CEO Bio

Mr. Paul Baehr has been the Chairman and Chief Executive Officer of IBEX Technologies, Inc. since October 1995 and serves as its President. Mr. Baehr serves as the President of Bio-Research Products, Inc. He served as the Chief Executive Officer of Bio-Research Products, Inc. He served as a Interim Director of Finance at IBEX Technologies from March 22, 2013 to June 25, 2013. Previously, Mr. Baehr served as an Executive Vice President, Sterling, Winthrop Pharmaceutical Division, New York. Prior thereto, he served as a Senior Vice President at CIBA-GEIGY Pharmaceuticals. He has been a Director of IBEX Technologies Inc. since 1995. He has been an Independent Director at Transition Therapeutics Inc. since December 2002. He served as a Director of Haemacure Corp., since May 1998. He served as a Director of NeuroMedix, Inc. Mr. Baehr holds a B.A. from the University of British Columbia.

CEO Compensation
  • Paul's compensation has been consistent with company performance over the past year.
  • Paul's remuneration is lower than average for companies of similar size in Germany.
Management Team

Paul Baehr

TITLE
President
COMPENSATION
CA$231K
AGE
75

Richard Collin

TITLE
Director of Finance & Secretary
COMPENSATION
CA$162K
TENURE
6 yrs

Claire Bergeron

TITLE
Vice President of Administration
COMPENSATION
CA$171K
TENURE
22.3 yrs
Board of Directors Tenure

Average tenure and age of the IBEX Technologies board of directors in years:

1.5
Average Tenure
72
Average Age
  • The average tenure for the IBEX Technologies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Paul Baehr

TITLE
President
COMPENSATION
CA$231K
AGE
75

Robert DeLuccia

TITLE
Lead Director
COMPENSATION
CA$41K
AGE
72

Danilo Netto

TITLE
Independent Director
COMPENSATION
CA$39K
TENURE
11.4 yrs

Joseph Zimmermann

TITLE
Director
COMPENSATION
CA$37K
TENURE
1.5 yrs

Bruce Connop

TITLE
Director
COMPENSATION
CA$42K
AGE
49
TENURE
1.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess IBEX Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. IBEX Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IBT News

Simply Wall St News

IBT Company Info

Description

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides services, such as filling and lyophilization of diagnostic disposables for medical devices; and custom fermentation and purification of enzymes, as well as contract manufacturing. Further, the company makes and sells proteins extracted from botanicals. It serves manufacturers of medical devices, quality control labs, and academic research institutions. The company was founded in 1986 and is based in Montreal, Canada.

Details
Name: IBEX Technologies Inc.
IBT
Exchange: DB
Founded: 1986
CA$2,471,582
24,773,244
Website: http://www.ibex.ca
Address: IBEX Technologies Inc.
5485 Paré Street,
Suite 100,
Montreal,
Quebec, H4P 1P7,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV IBT Common Shares TSX Venture Exchange CA CAD 14. Mar 1996
OTCPK IBXN.F Common Shares Pink Sheets LLC US USD 14. Mar 1996
DB IBT Common Shares Deutsche Boerse AG DE EUR 14. Mar 1996
Number of employees
Current staff
Staff numbers
0
IBEX Technologies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 20:51
End of day share price update: 2019/04/18 00:00
Last earnings filing: 2019/03/22
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.